Corcept Therapeutics (CORT) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 -1.05%
Revenue Growth %: +54.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +54.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.03, $0.02 better than the analyst estimate of $0.01. Revenue for the quarter came in at $19.7 million versus the consensus estimate of $18.36 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
- UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
